Department of Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Clin Transl Oncol. 2024 Feb;26(2):468-476. doi: 10.1007/s12094-023-03268-5. Epub 2023 Jul 7.
The purpose of this meta-analysis is to evaluate the efficacy and safety of TAS-102 in treating metastatic colorectal cancer (mCRC) using the most recent data available.
The literature on the efficacy and safety of TAS-102 versus placebo and/or best supportive care (BSC) in mCRC was obtained through a systematic search of PubMed, Embase, and Web of Science databases through January 2023. Identify the included literature and extract pertinent data, such as the overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF), disease control rate (DCR), incidence of adverse events (AEs) and serious adverse events (SAEs).
There were eight eligible articles that included 2903 patients (1964 TAS-102 versus 939 Placebo and/or BSC). In this meta-analysis, TAS-102 treatment resulted in longer OS, PFS, TTF, and higher DCR in patients with mCRC versus placebo and/or BSC. TAS-102 improved OS and PFS in subgroup analyses of mCRC patients with KRAS wild-type and KRAS mutant-type. In addition, TAS-102 did not increase the incidence of serious adverse events.
TAS-102 can enhance the prognosis of mCRC patients whose standard therapy has failed, regardless of KRAS mutation status, and its safety is acceptable.
本荟萃分析旨在利用最新可用数据评估 TAS-102 治疗转移性结直肠癌（mCRC）的疗效和安全性。
通过系统检索 PubMed、Embase 和 Web of Science 数据库，获取 TAS-102 与安慰剂和/或最佳支持治疗（BSC）在 mCRC 中的疗效和安全性的文献。确定纳入的文献并提取相关数据，如总生存期（OS）、无进展生存期（PFS）、治疗失败时间（TTF）、疾病控制率（DCR）、不良事件（AE）和严重不良事件（SAE）发生率。
有 8 篇符合条件的文献纳入了 2903 名患者（1964 名 TAS-102 与 939 名安慰剂和/或 BSC）。在这项荟萃分析中，与安慰剂和/或 BSC 相比，TAS-102 治疗可使 mCRC 患者的 OS、PFS、TTF 更长，DCR 更高。TAS-102 改善了 KRAS 野生型和 KRAS 突变型 mCRC 患者的 OS 和 PFS。此外，TAS-102 并未增加严重不良事件的发生率。
TAS-102 可改善标准治疗失败的 mCRC 患者的预后，无论 KRAS 突变状态如何，且安全性可接受。
